Skip to content

Cannabis: all studies

Page 268 of 287: studies 2,671 to 2,680 of 2,864, newest first. Back to the cannabis overview

Research

Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users.

Journal of Psychopharmacology September 2009 K Allott, B K Canny, J H Broadbear et al.

Despite evidence that +/-3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') causes persistent alterations to the serotonergic system of animals, evidence for long-term neurological effects of ecstasy/MDMA in humans remains equivocal. The current study assessed serotonin functioning of nine male and 11 female recreational ecstasy polydrug users by measuring neuroendocrine (prolactin, cortisol)...

Withdrawal phenomena and dependence syndrome after the consumption of "spice gold".

Deutsches Arzteblatt international July 3, 2009 Ulrich S Zimmermann, Patricia R Winkelmann, Max Pilhatsch et al.

Background: "Spice" and other herbal blends were marketed in Germany until January 2009 as substances purportedly exerting similar effects to cannabis, yet containing no cannabinoids. These products were recently forbidden in Germany under the provisions of the German Narcotics Law after they were found to contain undeclared, synthetic cannabinomimetic substances. The authors describe physical...

DOI: 10.3238/arztebl.2009.0464 (opens in new tab) Full text (opens in new tab) Humans Substance-related disorders Substance withdrawal syndrome Cannabinoids +7

Simple and Rapid Screening for Psychotropic Natural Products Using Direct Analysis in Real Time (DART)-TOFMS

Yakugaku Zasshi June 1, 2009 Maiko Kawamura, Yukihiro Goda, Ruri Kikura-Hanajiri 19 citations

Direct Analysis in Real Time (DART) is a novel ionization technique that provides for the rapid ionization of small molecules under ambient conditions. To investigate the trend of non-controlled psychotropic plants of abuse in Japan, a rapid screening method, without sample preparation, was developed using DART-time of flight mass spectrometer (TOFMS) for plant products. The major psychotropic...

DOI: 10.1248/yakushi.129.719 (opens in new tab) Dart ion source Mass spectrometry Noscapine Chromatography +2

The effects of cannabinoids on serum cortisol and prolactin in humans.

Psychopharmacology May 2009 Mohini Ranganathan, Gabriel Braley, Brian Pittman et al.

Cannabis is one of the most widely used illicit substances, and there is growing interest in the therapeutic applications of cannabinoids. While known to modulate neuroendocrine function, the precise acute and chronic dose-related effects of cannabinoids in humans are not well-known. Furthermore, the existing literature on the neuroendocrine effects of cannabinoids is limited by small sample...

Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog.

Psychopharmacology April 2009 Torbjörn U C Järbe, Chen Li, Qian Liu et al.

To characterize in vivo the high-affinity CB(1) cannabinoid receptor (CB(1)R) selective anandamide analog AM1346 [alkoxyacid amide of N-eicosa-tetraenylamine] using drug discrimination. Substitution tests involved Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and R-(+)-methanandamide (mAEA), a metabolically stable analog of anandamide (AEA), as well as the CB(1)R antagonist/inverse agonist...

Current Drug Scheduling Reviews Reported by DEA

The FASEB Journal April 1, 2009 Sandy Ghozland, Srihari R. Tella, Michelle D. Walker et al.

Pursuant to the Controlled Substances Act (CSA), DEA collects and reviews scientific, medical and other data for substances with abuse potential for possible placement under the CSA. The administrative process for scheduling is ongoing for indiplon, carisoprodol, dextromethorphan, salvinorin A and several petitions requesting a change in the control status of nabilone, methylphenidate product,...

DOI: 10.1096/fasebj.23.1_supplement.588.1 (opens in new tab) Drug control Hallucinogen Pharmacology Controlled substance

Psychosis: A Category or a Dimension?

The Canadian Journal of Psychiatry March 1, 2009 Emmanuel Stip 4 citations

Can J Psychiatry. 2009;54(3): 137-139. The diagnostic entity of schizophrenia creates a loose boundary around a heterogeneous collection of interrelated and relatively distinct phenotypes. The Diagnostic and Statistical Manual of Mental Disorders (DSM)-V planning process is currently under way and it has once again ignited the debate about the boundaries of this diagnosis. One question concerns...

Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

Psychopharmacology March 2009 Deepak Cyril D'Souza, Brian Pittman, Edward Perry et al.

Acute and chronic exposure to cannabinoids has been associated with cognitive deficits, a higher risk for schizophrenia and other drug abuse. However, the precise mechanism underlying such effects is not known. Preclinical studies suggest that cannabinoids modulate brain-derived neurotrophic factor (BDNF). Accordingly, we hypothesized that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the...

Endocannabinoid Signaling and Long-term Synaptic Plasticity

Annual Review of Physiology February 12, 2009 Boris D. Heifets, P. Castillo

Endocannabinoids (eCBs) are key activity-dependent signals regulating synaptic transmission throughout the CNS. Accordingly, eCBs are involved in neural functions ranging from feeding homeostasis to cognition. There is great interest in understanding how exogenous (e.g. cannabis) and endogenous cannabinoids affect behavior. As behavioral adaptations are widely considered to rely on changes in...

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.

Best practice & research. Clinical endocrinology & metabolism February 2009 Fabrício A. Moreira, Maximilian Grieb, Beat Lutz

Both agonists (e.g. Delta(9)-tetrahydrocannabinol, nabilone) and antagonists (e.g. rimonabant, taranabant) of the cannabinoid type-1 (CB(1)) receptor have been explored as therapeutic agents in diverse fields of medicine such as pain management and obesity with associated metabolic dysregulation, respectively. CB(1) receptors are widely distributed in the central nervous system and are involved...